换一批A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: Applicability and relevance in Indian patients with stable cardiovascular disease.
第一作者：
P,Kerkar
第一单位：
Departments of Cardiology, Seth GS Medical College & KEM Hospital, Mumbai, 400012, India. Electronic address: prafullakerkar@rediffmail.com.
作者：
医学主题词
心血管疾病(Cardiovascular Diseases);纤维蛋白溶解药(Fibrinolytic Agents);人类(Humans);印度(India);年患病率(Morbidity);危险性评估(Risk Assessment);二级预防(Secondary Prevention);血栓溶解疗法(Thrombolytic Therapy)
DOI
10.1016/j.ihj.2018.06.006
PMID
30580865
发布时间
2020-02-25
- 浏览0
Indian heart journal
911-914页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
